Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension

NCT02382016 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT02382016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02382016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Lead sponsor
Actelion
Phase
Phase 4
Overall status
Completed
Start date
June 23, 2015
Completion date
October 31, 2018
Enrollment
85 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

portopulmonary hypertension